Framework for the acceptability of technological health innovations [25]. Dahkki Wezzie S. Lora (18139765)

Fáttát:

Comparative matrix: summary of Ag-RDT acceptability across countries. Dahkki Wezzie S. Lora (18139765)

Fáttát:

Attributes of interviews (N = 228). Dahkki Wezzie S. Lora (18139765)

Fáttát:

Signal strength of ADE at the drug level ranked by reports. Dahkki Jun Hua Lai (22676523)

Fáttát:

Outcomes distribution of drug patients with the top 50 positive signal frequency by 4 methods (ROR PRR IC MGPS). Dahkki Jun Hua Lai (22676523)

Fáttát:

Time-to-onset analysis using the Weibull distribution test. Dahkki Jun Hua Lai (22676523)

Fáttát:

Characteristics of AEs reports. Dahkki Jun Hua Lai (22676523)

Fáttát:

Top 50 drugs sorted by frequency of positive signals stratified by reporter – by 4 methods (ROR PRR IC MGPS). Dahkki Jun Hua Lai (22676523)

Fáttát:

Gender Difference analysis of the top 50 drugs ranked by frequency by four methods (ROR PRR IC MGPS). Dahkki Jun Hua Lai (22676523)

Fáttát:

Top 50 Drugs with positive signals by frequency – by four methods (ROR PRR IC MGPS). Dahkki Jun Hua Lai (22676523)

Fáttát:

Two-by-two contingency table for disproportionality analysis. Dahkki Jun Hua Lai (22676523)

Fáttát:

The top 50 drugs by frequency of positive signals stratified by sex – by 4 methods (ROR PRR IC MGPS). Dahkki Jun Hua Lai (22676523)

Fáttát:

Flowchart. Dahkki Jun Hua Lai (22676523)

Fáttát:

The top 25 drugs sorted by frequency of positive signals stratified by age – by 4 methods (ROR PRR IC MGPS). Dahkki Jun Hua Lai (22676523)

Fáttát:

The principles of disproportionate measurement and the criteria for signal detection. Dahkki Jun Hua Lai (22676523)

Fáttát: